

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number  
**WO 01/43789 A1**

- (51) International Patent Classification<sup>7</sup>: A61L 31/12, 27/48
- (21) International Application Number: PCT/US00/33971
- (22) International Filing Date:  
14 December 2000 (14.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/466,697 17 December 1999 (17.12.1999) US
- (71) Applicant: GENZYME CORPORATION [US/US];  
One Kendall Square, Cambridge, MA 02139 (US).
- (72) Inventors: GREENAWALT, Keith, E.; 52 St. Mary's  
Road, Milton, MA 02186 (US). BUTLER, Timothy, J.;  
115 Cedar Street Apt. #8, Malden, MA 01864 (US).
- (74) Agent: ALLISON, Richard, D.; Genzyme Corporation,  
15 Pleasant Street Connector, Framingham, MA 01701-  
9322 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *With international search report.*  
— *Before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments.*
- For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: SURGICAL PROSTHESIS



(57) Abstract: A surgical prosthesis having a non-bioabsorbable layer and a bioabsorbable layer including hyaluronic acid and carboxymethyl cellulose, a method of manufacturing the prosthesis using an adhesive, and a method of using the surgical prosthesis to seal an opening in the body of the patient are disclosed.

WO 01/43789 A1

5

## SURGICAL PROSTHESIS

## BACKGROUND OF THE INVENTION

An unwanted opening in a body cavity, such as an incisional hernia, is often repaired using a prosthetic mesh (e.g., a polypropylene mesh) to line the inner surface of the body cavity wall at the opening. Viscera in the body cavity display a strong tendency to adhere to exposed mesh during the healing process. This tendency frequently results in significant postoperative complications.

## SUMMARY OF THE INVENTION

In general, the invention provides a laminated surgical prosthesis and methods of making and using the prosthesis. The prosthesis includes a non-bioabsorbable layer having an outer wall-facing surface and an inner bioabsorbable layer-facing surface, an adhesive, and a bioabsorbable layer containing hyaluronic acid (HA) and/or carboxymethyl cellulose (CMC). The HA and CMC (HA/CMC) can be chemically modified e.g., as described in U.S. Patent No. 5,017,229.

The non-bioabsorbable layer can be a mesh of polypropylene or poly(ethylene terephthalate).

The bioabsorbable layer has an outer viscera-facing surface and an inner non-bioabsorbable layer-facing surface which is attached to the bioabsorbable layer-facing surface by the adhesive. In addition, the inner non-bioabsorbable layer-facing surface of the bioabsorbable layer is preferably porous to facilitate binding with the inner bioabsorbable layer-facing surface of the non-bioabsorbable layer. The pores can be about 10-500  $\mu\text{m}$  in diameter, (e.g., 30-300 or 40-100  $\mu\text{m}$  in diameter) and can traverse the bioabsorbable layer from the outer viscera-facing surface to the inner non-bioabsorbable layer-facing surface. The amount of HA and CMC in the bioabsorbable layer can vary. In one example, the ratio of the amount of HA to the amount of CMC is between 1:0.01 and 0.01:1. Exemplary HA:CMC ratios are 1:2, 1:1 and 2:1.

The various layers of the prosthesis can have selected densities as follows. The non-bioabsorbable layer may have a density of about 6.3 to 9.5  $\text{g}/\text{ft}^2$  (e.g., 7.9  $\text{g}/\text{ft}^2$ ). The

5 bioabsorbable layer may have a density of about 2.0 to 4.5 g/ft<sup>2</sup> (e.g., 3.0 g/ft<sup>2</sup>). The adhesive may have a density of about 2.7 to 4.1 g/ft<sup>2</sup> (e.g., 3.4 g/ft<sup>2</sup>).

The adhesive is preferably bioabsorbable and may contain polyglycolic acid, polylactic acid, polycaprolactone, polydioxanone, polyester carbonate, polyhydroxyalkonate, or copolymers thereof. For example, the adhesive can be a 1:1 copolymer of polyglycolic  
10 acid and polylactic acid.

The invention also includes a method of repairing an opening in a wall enclosing a body cavity by positioning the surgical prosthesis of the invention over the opening and in contact with an inner surface of the wall, then closing the opening. The method of repairing an opening in a wall may also preferably include securing the prosthesis to the wall, e.g., by  
15 suturing.

In addition, the invention features a method of producing a surgical prosthesis by applying an adhesive to a surface of a non-bioabsorbable sheet, and adhering a bioabsorbable composition to the surface of the non-bioabsorbable sheet subsequent to the application of the adhesive to the surface of the non-bioabsorbable sheet. The composition preferably contains  
20 hyaluronic acid and/or carboxymethyl cellulose. The adhering step may include placing the bioabsorbable composition onto the surface of the non-bioabsorbable sheet and heat-pressing the composition in a process such as lamination.

As used herein, "non-bioabsorbable layer" means a layer that contains components that are not readily absorbed, degraded, or otherwise decomposed when present in a body  
25 cavity (e.g., the human peritoneal cavity).

As used herein, "bioabsorbable layer" means a layer containing components that can be degraded or absorbed at some time after implantation of the prosthesis, such as within weeks or months following implantation. The bioabsorbable products are preferably eliminated from the body or metabolized.

30 As used herein, "hyaluronic acid" and "carboxymethyl cellulose" means those compounds and the chemical derivatives thereof, e.g., as described in U.S. Patent No. 5,017,229.

As used herein, "heat-pressing" means a process that involves pressing at least two materials into contact with each other while heat is applied to at least one of the materials.

- 5 Other features and advantages of the invention will be apparent from the following detailed description, figures, and claims.

### BRIEF DESCRIPTION OF THE DRAWING

Fig. 1 is a perspective view of a prosthesis of the invention, with the bioabsorbable (HA/CMC) layer and adhesive partially separated from the non-bioabsorbable layer.

Fig. 2 is a plan view of an opening in a wall of a body cavity before repair.

Fig. 3 is a plan view of the opening in Fig. 2 with the prosthesis shown in Fig. 1 properly positioned for repair.

Fig. 4 is a plan view of the opening and prosthesis in Fig. 3, the opening now being closed by sutures.

Fig. 5 is a cross sectional view of the repaired wall taken at line 36 shown in Fig. 4.

### DETAILED DESCRIPTION

In general, the invention relates to a surgical prosthesis having at least three layers. A first non-bioabsorbable layer, is made of a material such as polypropylene and can have a thickness of about 400 to 650 microns or a density of about 6.3 to 9.5 g/ft<sup>2</sup> (e.g., 7.9 g/ft<sup>2</sup>). A second layer that is bioabsorbable is made from a material such as hyaluronic acid, carboxymethyl cellulose, or mixtures thereof and can have a thickness of about 150 to 300 microns or a density of about 2.0 to 4.5 g/ft<sup>2</sup> (e.g., 3.0 g/ft<sup>2</sup>). The first and second layers are affixed to each other by a third layer, i.e., an adhesive, formed of a material such as a copolymer of polylactic acid and polyglycolic acid. The third layer can have a thickness of about 25 to 200 microns or a density of about 2.7 to 4.1 g/ft<sup>2</sup> (e.g., 3.4 g/ft<sup>2</sup>).

Referring to Fig. 1, a prosthesis 10 includes a non-bioabsorbable mesh 12 made of a polymer such as polypropylene or poly(ethylene terephthalate). The mesh may include woven strands, a woven mesh of fibers, a preformed square pattern, or similar configurations. Mesh 12 includes a wall-facing surface 20 and a bioabsorbable layer-facing surface 18. Bioabsorbable layer 14 is preferably formed of HA and CMC and has non-bioabsorbable layer-facing surface 22 affixed to bioabsorbable layer-facing surface 18 of mesh 12 by an adhesive 16. The adhesive 16 may be, for example, a 1:1 copolymer of polyglycolic acid and

5 polylactic acid. The bioabsorbable layer 14 also includes a viscera-facing surface 24. The bioabsorbable layer 14 contains pores 26 that are adjacent to the non-bioabsorbable layer-facing surface and more preferably traverse the layer from viscera-facing surface 24 to non-bioabsorbable layer-facing surface 22. Although the pores traverse the layer in this particular embodiment, it is to be understood that in other embodiments (not shown), the pores may not  
10 traverse the entire bioabsorbable layer. During manufacturing, the adhesive 16 preferably infiltrates the pores 26 and facilitates the binding of bioabsorbable layer 14 to the mesh 12.

In some embodiments the wall-facing surface 20 and the viscera facing surface 24 of the bioabsorbable layer 14 differ in coloration, visible surface markings or a tactile feature. This facilitates identification of the respective surfaces and proper orientation of the  
15 prosthesis 10 by the surgeon.

As shown in the drawings, the prosthesis 10 may be used to repair an opening 28 in a wall 30 of a body cavity 32 that contains a viscera surface 34 (e.g., bowel, omentum, etc.). To repair the opening 28, the prosthesis 10 is inserted into body cavity 32 at opening 28. The prosthesis 10 is positioned so the wall-facing surface 20 of mesh 12 covers the opening 28 of  
20 the body cavity 32 with the wall-facing surface 20 facing the wall 30 of the body cavity, and the bioabsorbable layer-facing surface 18 faces the viscera 34. The bioabsorbable layer 14 covers the bioabsorbable layer-facing surface 18 and protects the viscera 34 from adhering to the mesh 12 during healing. The repair of the opening 28 in body cavity 32 is then completed by closing the opening 28 with sutures 38.

25 In time, the bioabsorbable layer 14 is absorbed by the body, leaving bioabsorbable layer-facing surface 18 of the mesh 12 directly facing the viscera 34. However, by the time bioabsorbable layer 14 is absorbed, the opening 28 has healed to an extent where the tendency to form adhesions between the wall 30 of the body cavity and the mesh 12 has abated. This abatement is the result of the reestablishment of a mesothelial lining on the  
30 inside surface of wall 30, over healed opening 28. During the healing process, the mesh 12 attaches to the wall of the body cavity.

Based on the above description and the examples described below, one skilled in the art can utilize the present invention to its fullest extent. The following examples are illustrative of how one skilled in the art may make and use the prosthesis of the invention and

- 5 are not to be construed as limiting the remainder of the disclosure in any way. Any publications cited in this disclosure are hereby incorporated by reference.

#### Example 1

10 A 1 x 1 inch piece of polycaprolactone/polyglycolic acid (PCL/PGA) 90/10 copolymer film (at a density of about 8 g/ft<sup>3</sup>) was placed on top of a 1 x 1 inch piece of MARLEX® polypropylene mesh.

A HA/CMC composition was produced generally following the procedures described in U.S. Patent No. 5,017,229. A carbodiimide modified HA/CMC powder was suspended in deionized H<sub>2</sub>O at a concentration of 1% (w/v) using a high shear blender (Turrax T50 with  
15 G45F head) for 10 minutes. The HA/CMC suspension was poured into a polystyrene tray or TEFLON®-coated stainless steel tray at a density of 4 g/ft<sup>3</sup> and lyophilized into solid foam sheets. The shelf temperature was ramped down to -20°C at a rate of 0.1°C/min. The drying cycle was initiated with vacuum set at less than or equal to 150 mtorr, and the shelf  
20 temperature was raised at 0.1°C/min to -12°C. The shelf temperature was held at -12°C for 180 minutes and then raised at 0.1°C/min to 0°C. The shelf temperature was then held at 0°C for 900 minutes and then raised at 0.1°C/min to 27°C. The foam sheet was removed after the foam temperature reached the shelf temperature. Scanning electron microscopy of the resulting foam indicated a range of pore sizes about 50-300 µm in diameter.

A 1 x 1 inch piece of HA/CMC foam was placed on top of the PCL/PGA film, which  
25 was on top of the polypropylene mesh. This configuration was placed between two TEFLON®-coated stainless steel plates and pressed in a Carver Laboratory Press. The conditions for lamination were 250°F for 30 seconds with no pressure, then 15 seconds at 2 metric tons of pressure. The prosthesis was removed from the press, allowed to cool, and then removed from between the TEFLON®-coated stainless steel plates. The HA/CMC  
30 component of the one piece prosthesis did not exhibited any discoloration, nor did the polypropylene show signs of melting. In addition, the various layers of the prosthesis were well-incorporated into adjacent layers.

5     Example 2

          A 2 x 2 inch piece of PCL/PGA 95/5 copolymer film (at a density of 8 g/ft<sup>2</sup>) was placed on top of a 2 x 2 inch piece of MARLEX® polypropylene mesh. Then a 2 x 2 inch piece of HA/CMC foam, produced according to Example 1, was placed on top of the PCL/PGA film. This sandwich was placed between two TEFLON® sheets with a 0.4 mm  
10     spacer and then pressed between chrome plates using a Carver Laboratory Press. The spacer is a metal shim placed between the chrome plates that allows for the maintenance of a pre-determined gap thickness and prevents pressing the mesh completely through the surface of the foam. The conditions for lamination were 220°F for 45 seconds with no pressure, then 15  
15     seconds at 2 metric tons pressure. The material was removed from the press, allowed to cool at 4°C. and then removed from the plates. The PCL/PGA, HA/CMC foam, and mesh components were all well-incorporated into adjacent layers in the prosthesis.

          To determine whether the adhesive was necessary to produce a well-adhered, uniform distribution of HA/CMC over the polypropylene mesh, a 1.25 x 4.125 inch piece of mesh was placed in a TEFLON®-coated tray. A 0.6% (w/v) suspension of HA/CMC was poured over  
20     the mesh to achieve a density of 4.5 g/ft<sup>2</sup> and lyophilized into a solid foam sheet as described in Example 1. The distribution of the HA/CMC foam matrix on the polypropylene mesh was uneven, with regions of the mesh having dense coverage of HA/CMC and other regions of the mesh having light coverage of HA/CMC. Thus, the adhesive was desirable for producing a prosthesis having an even distribution of HA/CMC over a mesh.

25     The role of the adhesive in the preparation of the prosthesis was further investigated by eliminating the adhesive in another method for producing a prosthesis. A 1 x 1 inch piece of HA/CMC foam produced as described in Example 1 was placed on top of a 1 x 1 inch piece of MARLEX® polypropylene mesh, then pressed between two TEFLON®-coated stainless steel plates using a Carver Laboratory Press. The foam and mesh were then  
30     laminated by heating at 330-350°F for 30 seconds with no pressure, then for 15 seconds at 2 metric tons of pressure. The prosthesis was removed from the press, allowed to cool, and removed from the stainless steel plates. There was poor or no incorporation of the HA/CMC foam into the mesh. Thus, the adhesive was desirable for incorporation of the layers of the prosthesis into adjacent layers. In addition, it was concluded that the relatively neutral (in

- 5 terms of hydrophobicity) adhesive facilitated contact between two dislike materials: a hydrophobic non-bioabsorbable synthetic polymer mesh and a hydrophilic bioabsorbable polymer.

### Example 3

- 10 HA/CMC foam produced according to Example 1 was subjected to dehydrothermal treatment (DHT) at 100°C for 6 hours. A 2.25 x 2.25 inch piece of polyglycolic acid/polylactic acid (PGA/PLA) 50/50 copolymer film (at a density of about 6 g/ft<sup>3</sup>) was placed on top of a 2.25 x 2.25 inch piece of the foam after DHT. Then the 2.25 x 2.25 inch piece of MARLEX® polypropylene mesh was placed on top of the PGA/PLA film. This  
15 configuration was placed between two TEFLON® sheets with a 0.4 mm spacer and pressed between two chrome plates using a Carver Laboratory Press. The conditions for lamination were 240°F for 45 seconds with no pressure, then pressing for 20 seconds at 3000 pounds (lb) pressure. The material was removed from the press, allowed to cool at 4°C, and then removed from the plates. The PGA/PLA, HA/CMC foam, and mesh components were all  
20 well-incorporated into adjacent layers in the prosthesis.

### Example 4

- Two 3 x 3 inch pieces of HA/CMC foam made according to Example 1 and two 3 x 3 inch pieces of MARLEX® polypropylene mesh were each spray-coated on one surface with a  
25 3% (w/v) solution of PGA/PLA 50/50 copolymer in methylene chloride to achieve a 15% final weight gain. All four pieces were individually packaged in Chex-All® II pouches and subjected to (DHT) at 100°C for 6 hours. Then a single foam piece was placed on top of a single MARLEX® piece, with the spray-coated surface of one piece contacting the spray-coated surface of the other piece. This configuration was placed between two TEFLON®  
30 sheets with a 1.45 mm spacer and pressed between two chrome plates using a Carver Laboratory Press. The conditions for lamination were 240°F for 1 minute with no pressure, then 30 seconds at 7000 lb pressure. The material was removed from the press, allowed to cool at 4°C, and then removed from the plates. The PGA/PLA, HA/CMC foam, and mesh



5 components were all well-incorporated into adjacent layers in the prosthesis. This procedure was repeated for the remaining two pieces.

To determine the desirability of the porous nature of the HA/CMC foam in the prostheses produced immediately above, a 2 x 2 inch piece of non-porous, glycerol plasticized HA/CMC film and a 2 x 2 inch piece of BARD® mesh (Davol, Inc.) were spray-  
10 coated on a surface with a 3% (w/v) solution of PGA/PLA 50/50 copolymer in methylene chloride to achieve a 15% final polymer weight gain for each of the film and mesh. The non-porous HA/CMC film was placed on top of the mesh with the spray-coated surfaces contacting each other. This configuration was placed between two TEFLON® sheets with a 0.625 mm spacer and then pressed between two chrome plates using a Carver Laboratory  
15 Press. The film and mesh were then laminated at 240°F for 1 minute with no pressure, then for 45 seconds at 1000 lb pressure. The prosthesis was removed from the press, allowed to cool in a 2-8°C cold room, and removed from between the chrome plates. The prosthesis exhibited little, if any, infiltration of the mesh by the film, in contrast to the prosthesis having the porous HA/CMC foam.

20 The practical effect of the minimal infiltration in the nonporous HA/CMC film prosthesis was also compared to the porous HA/CMC foam prosthesis. Both types of prostheses produced in this Example were evaluated for surgical handling and placement properties in a rabbit hernia repair model (Dinsmore, The American Surgeon 65:383-387, 1999). When the prosthesis having the porous HA/CMC foam layer was prehydrated prior to  
25 the surgical insertion, the prosthesis did not delaminate. The prosthesis could be handled adequately to surgically repair the defect in the animal. In contrast, the prosthesis having the nonporous HA/CMC film layer delaminated into two pieces when prehydrated and was not able to be used to repair the body cavity opening in the rabbit hernia repair model.

To evaluate the physical strength and integrity of the porous HA/CMC foam  
30 prosthesis versus the nonporous HA/CMC film prosthesis, the wet bond strength of each was determined using an in vitro phosphate buffered saline (PBS) immersion assay. 1 x 1 inch sample prostheses were each placed into a 50 ml vial filled with 30 ml of PBS. The vials were then moderately agitated at 37°C. The samples were then removed from the vials, placed in 100% ethanol to remove the water, and then stained with the dye alcian blue, which

- 5 binds to HA. The extent of staining correlated with the amount of HA remaining on a mesh. The results from the PBS immersion assay are summarized in Table 1.

TABLE 1

<u>Test Group</u>	<u>Duration of Immersion</u>	<u>Assessment</u>
Foam Prosthesis	2 hours	HA present; 100% of mesh covered with dark blue staining
Film Prosthesis	2 hours	no HA present; no staining
Foam Prosthesis	6 hours	HA present, 100% of mesh covered with dark blue staining
Film Prosthesis	6 hours	no HA present, no staining

10

The lack of staining for the nonporous film prosthesis appeared to be due to delamination of the film from the mesh after 2 or more hours of immersion. In contrast, the porous foam prosthesis retained HA after 6 hours of immersion.

15 Example 5

The prosthesis having a porous HA/CMC foam layer prepared in Example 4 was further evaluated in a rat hernia repair model (Dinsmore, supra) and was compared with the performance of MARLEX® polypropylene mesh only. A 1 x 1 inch full thickness defect was excised from the rectus abdominis muscle of rats to prepare the animal model. The defect was repaired by suturing the test material into the defect using a continuous suture pattern. In one set of animals, the composite prosthesis was used for repair of the hernia, with the HA/CMC layer facing the viscera. In another set of animals, MARLEX® mesh only was used for repair of the hernia. The rats were sacrificed 28 days after repair and graded for

- 5 adhesion formation using the following scale: 0 = no adhesions, 1 = less than or equal to 25% of the defect covered by adhesions, 2 = 26 to 50% of the defect covered by adhesions, 3 = 51 to 75% of the defect covered by adhesions, and 4 = greater than 75% of the defect covered by adhesions. The results are shown in Table 2.

**TABLE 2**

<u>Test Group</u>	<u>Average Extent of Adhesions</u>	<u>% of Animals w/no Adhesions</u>
Polypropylene Mesh Only (n=5)	3.0 ± 1.0	0
Composite Prosthesis (n=10)	0.7 ± 0.7*	40

- 10 \*Significantly different from mesh only group (Tukey-Kramer,  $p \leq 0.05$ )  
Average extent of adhesions is expressed as the mean ± one standard deviation.

The results in Table 2 indicated that the composite prosthesis of the invention was superior to the polypropylene mesh in preventing adhesions in vivo.

- 15 Other embodiments are included within the following claims. For example, the bioabsorbable layer may contain chitosan, alginate, or other bioabsorbable materials or combinations of materials. In addition, the prosthesis may contain a protein drug, non-steroidal anti-inflammatory drug, small molecule drug, or the like. The drug may be incorporated in any portion of the prosthesis (e.g., the bioabsorbable layer or the adhesive) to  
20 provide for the controlled release of the drug into the body cavity to be repaired with the prosthesis. Similarly, the mesh layer may be formed of a variety of materials that are not reactive or minimally reactive with the tissue of the patient.

- Although the preferred form of the present invention has been described above, such description is for illustrative purposes only, and it is to be understood that changes and  
25 variations may be made to the present invention without departing from the spirit or scope of the following claims.

5        Claims

We claim:

1. A surgical prosthesis comprising  
a non-bioabsorbable layer having an outer wall-facing surface and an inner  
10 bioabsorbable layer-facing surface;  
an adhesive; and  
a bioabsorbable layer comprising a material selected from the group consisting of  
hyaluronic acid and carboxymethyl cellulose, the bioabsorbable layer having an outer viscera-  
facing surface and an inner non-bioabsorbable layer-facing surface attached to the  
15 bioabsorbable layer-facing surface of the non-bioabsorbable layer by the adhesive, wherein  
the bioabsorbable layer contains pores in the non-bioabsorbable layer-facing surface.
2. The prosthesis of claim 1, wherein the non-bioabsorbable layer comprises  
polypropylene.  
20
3. The prosthesis of claim 1, wherein the non-bioabsorbable layer comprises  
poly(ethylene terephthalate).
4. The prosthesis of claim 1, wherein the non-bioabsorbable layer is a mesh.  
25
5. The prosthesis of claim 1, wherein the adhesive is bioabsorbable.
6. The prosthesis of claim 1, wherein the adhesive comprises polyglycolic acid.
- 30 7. The prosthesis of claim 1, wherein the adhesive comprises polylactic acid.
8. The prosthesis of claim 1, wherein the adhesive comprises a copolymer of  
polylactic acid and polyglycolic acid.

- 5           9. The prosthesis of claim 8, wherein the ratio of the total amount of polyglycolic acid to the total amount of polylactic acid in the adhesive is about 1:1.
10. The prosthesis of claim 1, wherein the adhesive comprises a polymer selected from the group consisting of polycaprolactone, polydioxanone, polyestercarbonate, and  
10   polyhydroxyalkonate.
11. The prosthesis of claim 1, wherein the bioabsorbable layer comprises hyaluronic acid and carboxymethyl cellulose.
- 15           12. The prosthesis of claim 11, wherein the ratio of the total amount of hyaluronic acid to the total amount of carboxymethyl cellulose in the bioabsorbable layer is about 2:1.
13. The prosthesis of claim 1, wherein the pores traverse the bioabsorbable layer from the viscera-facing surface to the non-bioabsorbable layer-facing surface.  
20
14. The prosthesis of claim 11, wherein the pores are about 10-500  $\mu\text{m}$  in diameter.
15. The prosthesis of claim 14, wherein the pores are about 30-300  $\mu\text{m}$  in diameter.
- 25           16. The prosthesis of claim 15, wherein the pores are about 40-100  $\mu\text{m}$  in diameter.
17. A method of repairing an opening in a wall enclosing a body cavity of a human patient, the method comprising  
          providing a surgical prosthesis formed of  
30           a non-bioabsorbable layer having a wall-facing surface and a bioabsorbable layer-facing surface,  
          an adhesive, and  
          a bioabsorbable layer comprising a material selected from the group consisting of hyaluronic acid and carboxymethyl cellulose, the bioabsorbable layer having a viscera-

5 facing surface and a non-bioabsorbable layer-facing surface attached to the bioabsorbable layer-facing surface by the adhesive, wherein the bioabsorbable layer contains pores in the non-bioabsorbable layer-facing surface;

positioning the surgical prosthesis over the opening of the patient, in contact with an inner surface of the wall; and

10 closing the opening.

18. The method of claim 17, wherein the non-bioabsorbable layer comprises a polymer selected from the group consisting of polypropylene and poly(ethylene terephthalate).

15

19. The method of claim 17, wherein the adhesive comprises a polymer selected from the group consisting of polyglycolic acid, polylactic acid, polycaprolactone, polydioxanone, polyester carbonate, polyhydroxyalkonate, and copolymers thereof.

20 20. The method of claim 17, wherein the bioabsorbable layer comprises hyaluronic acid and carboxymethyl cellulose.

21. The method of claim 20, wherein the ratio of the total amount of hyaluronic acid to the total amount of carboxymethyl cellulose in the bioabsorbable layer is about 2:1.

25

22. A method of producing a prosthesis, the method comprising providing a non-bioabsorbable sheet;

applying an adhesive to a surface of the non-bioabsorbable sheet; and

30 adhering a bioabsorbable composition to the surface subsequent to application of the adhesive to the surface, the bioabsorbable composition comprising a material selected from the group consisting of hyaluronic acid and carboxymethyl cellulose.

23. The method of claim 22, wherein the adhering step comprises placing the bioabsorbable layer onto the surface and heat-pressing the composition to the surface.

5

24. A surgical prosthesis comprising  
a non-bioabsorbable layer having an outer wall-facing surface and an inner  
bioabsorbable layer-facing surface;  
an adhesive; and

10

a bioabsorbable layer comprising a material selected from the group consisting of  
hyaluronic acid and carboxymethyl cellulose, the bioabsorbable layer having an outer viscera-  
facing surface and an inner non-bioabsorbable layer-facing surface attached to the  
bioabsorbable layer-facing surface of the non-bioabsorbable layer by the adhesive.

15

25. The prosthesis of claim 24, wherein the bioabsorbable layer contains pores that  
traverse the bioabsorbable layer from the viscera-facing surface to the non-bioabsorbable  
layer-facing surface.

20

26. A surgical prosthesis comprising  
a non-bioabsorbable layer having an outer wall-facing surface and an inner  
bioabsorbable layer-facing surface;  
an adhesive; and  
a bioabsorbable layer having an outer viscera-facing surface and an inner non-  
bioabsorbable layer-facing surface attached to the bioabsorbable layer-facing surface of the  
non-bioabsorbable layer by the adhesive, wherein the bioabsorbable layer contains pores in  
the non-bioabsorbable layer-facing surface.

25

30

27. A surgical prosthesis comprising  
a non-bioabsorbable layer having an outer wall-facing surface and an inner  
bioabsorbable layer-facing surface;  
an adhesive; and  
a bioabsorbable layer having an outer viscera-facing surface and an inner non-  
bioabsorbable layer-facing surface attached to the bioabsorbable layer-facing surface of the  
non-bioabsorbable layer by the adhesive, wherein the non-bioabsorbable layer has a density

- 5 of about 6.3 to 9.5 g/ft<sup>2</sup>, the bioabsorbable layer has a density of about 2.0 to 4.5 g/ft<sup>2</sup>, and the adhesive has a density of about 2.7 to 4.1 g/ft<sup>2</sup>.






FIG. 1




FIG. 2

3/5





FIG. 3

4/5



5/5




FIG. 5

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 00/33971

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61L31/12 A61L27/48

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, WPI Data, PAJ, EPO-Internal

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	GREENAWALT KEITH E ET AL: "Evaluation of Sepramesh biosurgical composite in a rabbit hernia repair model." JOURNAL OF SURGICAL RESEARCH, 'Online! vol. 94, no. 2, 1 November 2000 (2000-11-01), pages 92-98, XP002166286 Retrieved from the Internet: <URL:http://a96.g.akamaitech.net/n/96/1861/974908308000/extra.idealibrary.com/production/jsre/2000/94/2/jsre.2000.6020/6020a.pdf?sessionID=D2J5VJIAADFYCQAABYQAAA> 'retrieved on 2001-04-27! the whole document	1-27
P, X	WO 00 16822 A (BRIGHAM & WOMENS HOSPITAL) 30 March 2000 (2000-03-30) claims; examples	1-27

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

4 May 2001

Date of mailing of the international search report

17/05/2001

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

ESPINOSA, M

# INTERNATIONAL SEARCH REPORT

Internat. Application No  
PCT/US 00/33971

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 705 878 A (GENZYME CORP) 10 April 1996 (1996-04-10) claims; examples ---	1-27
A	US 5 632 979 A (GOLDBERG EUGENE P ET AL) 27 May 1997 (1997-05-27) claims; examples -----	1-27

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internatio. Application No

PCT/US 00/33971

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0016822	A	30-03-2000	NONE	
EP 0705878	A	10-04-1996	AU 707022 B	01-07-1999
			AU 3286095 A	18-04-1996
			CA 2159055 A	07-04-1996
			JP 8208706 A	13-08-1996
US 5632979	A	27-05-1997	US 5350573 A	27-09-1994
			US 5140016 A	18-08-1992
			US 5080893 A	14-01-1992
			US 6010692 A	04-01-2000
			WO 9518840 A	13-07-1995
			US 6086907 A	11-07-2000
			US 5290548 A	01-03-1994
			AT 117898 T	15-02-1995
			DE 68921002 D	16-03-1995
			DE 68921002 T	08-06-1995
			EP 0420877 A	10-04-1991
			JP 6077601 B	05-10-1994
			JP 3504602 T	09-10-1991
			WO 8911857 A	14-12-1989